Robert Dubois, National Pharmaceutical Council CSO and executive vice president, writes in an article published in the Journal of Clinical Pathways that personalized medicine and value-based models are “key directions” in today’s health care landscape.
However, Dubois writes, integrating personalized medicine and value frameworks is a challenging task.
” … When it comes to weighing the value of a medication, value assessments incorporate the perspectives and costs that are most relevant to health systems and payers – not the consequences that can impact patients and their families,” Dubois writes. “Value is much broader than cost.”
A number of organizations have already developed value-based frameworks, including the Institute for Clinical and Economic Review, the National Comprehensive Cancer Network and the American Society for Clinical Oncology.